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Adhesive small bowel obstruction (ASBO) is an adverse consequence of abdominal surgery. Although the Kampo medicine
Dai-kenchu-to is widely used in Japan for treatment of postoperative ASBO, rigorous clinical studies for its use have not
been performed. In the present retrospective observational study using the Japanese diagnosis procedure combination inpatient
database, we selected 288 propensity-score-matched patients with early postoperative ASBO following colorectal cancer surgery,
who received long-tube decompression (LTD) with or without Dai-kenchu-to administration. The success rates of LTD were not
signiﬁcantly diﬀerent between Dai-kenchu-to users and nonusers (84.7% versus 78.5%; P = .224), while Dai-kenchu-to users
showed a shorter duration of LTD (8 versus 10 days; P = .012), shorter duration between long-tube insertion and discharge (23
versus 25 days; P = .018), and lower hospital charges ($23,086 versus $26,950; P = .018) compared with Dai-kenchu-to nonusers.
In conclusion,the present study suggests that Dai-kenchu-to is eﬀective for reducing the duration of LTD and saving costs.
1.Introduction
Adhesive small bowel obstruction (ASBO) is an adverse
consequence of abdominal surgery, which can result in
overall prolonged recovery coupled with augmented patient
discomfort and an increased risk of postoperative compli-
cations [1, 2]. Approximately 3% of all surgical admissions
are attributable to intestinal adhesions following abdominal
surgeries [3]. In particular, colorectal cancer surgery is
considered a high risk of postoperative ASBO. A previous
report showed that intestinal obstruction due to adhesion
occurs in approximately 11% of patients who undergo total
colectomy [3].
Long-tube decompression (LTD) has been shown to be
successful for patients with clinically and radiographically
diagnosed ASBO, except for cases with contraindications
including strangulation, malignant obstruction, peritonitis,
and radiation enteritis [2, 4, 5]. A long tube is inserted
through the nose, esophagus, stomach, and duodenum. A
balloon is then inﬂated, and peristalsis advances the tube
to the point of obstruction, decompressing the bowel of
air and ﬂuids. In Japan, Dai-kenchu-to, which is a Kampo
medicine (traditional Japanese herbal medicine), is used for
prevention and treatment of postoperative ASBO [6, 7].
Dai-kenchu-to products are made by two diﬀerent Kampo2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Days after long-tube insertion and the rate of patients
who terminated long-tube decompression (LTD) in Dai-kenchu-to
(DKT) users and nonusers.
pharmaceutical companies (Tsumura and Kotaro). Both
products comprise the same ingredients as follows: extract
granules of 5.0g processed ginger (kankyo), 3.0g ginseng
(ninjin), and 2.0g zanthoxylum fruit (sansho)i nt h ed a i l y
dosage.
Several pharmacological mechanisms of Dai-kenchu-to
have been conﬁrmed mainly based on animal experiments,
including an increase in blood ﬂow in the intestinal tract
[8], direct stimulation of intestinal motility [9–12], and
prevention of bacterial translocation [13]. Previous studies
have also conﬁrmed that Dai-kenchu-to elevates levels of
neurotransmitters or hormones in human plasma, including
motilin, vasoactive intestinal polypeptide, calcitonin gene-
related peptide, serotonin, and substance P [14–17]. Several
clinical studies have suggested an eﬀect of Dai-kenchu-to
on postoperative ASBO patients. Orally administered Dai-
kenchu-to reduces postoperative ASBO-related symptoms
[6], the frequency of secondary laparotomy [18], and length
of hospital stay [19]. However, these previous studies were
based on a small number of patients. Forpatients with severe
postoperative ASBO requiring LTD, direct administration of
Dai-kenchu-to into the small intestine through a long tube
is often attempted in the Japanese clinical setting although
the eﬀect of such a method remains unclear [12, 20]. While
Dai-kenchu-to is widely used in Japan, rigorous clinical
studies are lacking and there is a paucity of data for assisting
physicians in other countries to make a decision on trying
this type of medicine for postoperative ASBO [6].
The purpose of this study was to investigate the
eﬀectiveness of transluminal Dai-kenchu-to administration
for patients with postoperative ASBO requiring LTD after
colorectal cancer surgery, using the diagnosis procedure
combination(DPC)inpatient database in Japan. We hypoth-
esized that transluminally administered Dai-kenchu-to is
eﬀective for reducing a secondary operation for removal of
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Figure 2: Days after long-tube insertion and the rate of patients
who were discharged in Dai-kenchu-to (DKT) users and nonusers.
intra-abdominal adhesion, duration of LTD, length of stay
and hospital charges.
2.Methods
2.1. Data Source. DPC is a Japanese case-mix classiﬁcation
system that is similar to the diagnosis-related groups in the
US medicare system. This patient classiﬁcation system was
launched in 2002 by the Ministry of Health, Labour, and
Welfare of Japan, and was linked with a lump-sum payment
system [21]. All of Japan’s 82 teaching hospitals are obliged
to adopt the DPC system, but community hospitals can
voluntarily adopt it. A survey of DPC hospitals is conducted
between July 1 and December 31 every year by the DPC
Research Group funded by the Ministry of Health, Labour,
and Welfare of Japan [22, 23]. Not only administrative
claims data but also detailed patient data are collected for all
inpatients discharged from participating hospitals between
July 1 and December 31. The survey began in 2003 with 82
teaching hospitals and the number of participating hospitals
has steadily increased, with 926 in 2007 and 855 in 2008.
The number of inpatients was 2.99 million in 2007 and 2.86
million in 2008. The number of inpatients in 2008 (2.86
million) represented approximately 40% of all inpatient
admissions to acute care hospitals in Japan.
The DPC database includes the following data: patients’
age and sex; main diagnoses, comorbidities at admission
and complications after admission recorded with the inter-
national classiﬁcation of diseases, tenth revision codes and
text data in the Japanese language, procedures coded with
the Japanese original codes, drugs and devices used, length
of stay (days), and in-hospital mortality.
The DPC database partially corresponds to the nation-
wide inpatient sample in the United States [24], but it
has several advantages. In the DPC database, complications
that occur after admission are clearly diﬀerentiated fromEvidence-Based Complementary and Alternative Medicine 3
comorbidities that were already presented at admission. For
example, we were able to separate ASBO that developed
prior to hospital admission from ASBO that developed
during hospitalization. For optimizing the accuracy of the
recorded diagnoses, physicians in charge are obliged to
record the diagnoses with reference to medical charts. The
dates when patients are admitted or discharged, and when
each procedure is performed, they are recorded using a
uniform data submission format. For example, the dates
when the long tube is inserted and removed and the
dates when administration of Dai-kenchu-to is started and
terminated are recorded.
All patient identiﬁers were removed from this database.
The requirement for informed consent was waived because
of the anonymous nature of the data. Study approval
was obtained from the institutional review board at the
University of Occupational and Environmental Health.
2.2. Patient Selection. First, among all the 5.9 million
inpatients between July 1 and December 31 in 2007 and
2008, we selected patients who underwent radical surgery
for colorectal cancer including colectomy, high anterior
resection of the rectum, low anterior resection of the rectum,
and abdominoperineal resection. Surgical approaches (open
or laparoscopic) were also identiﬁed. Second, we excluded
patientswithadiagnosisofstrangulationobstruction,malig-
nant obstruction, peritonitis, or radiation enteritis. We also
excluded patients with inﬂammatory bowel disease (Crohn’s
disease or ulcerativecolitis)because it has an intensive risk of
intra-abdominal adhesion [4]. Third, we identiﬁed patients
who started LTD after the date of colorectal cancer surgery
and selected the following two groups of patients: (1)
patients who used Dai-kenchu-to during the period of LTD,
that is, patients in whom Dai-kenchu-to was transluminally
administered though a long tube (Dai-kenchu-to users) and
(2) patients who did not use Dai-kenchu-to during the
whole period of hospitalization (Dai-kenchu-to nonusers).
2.3. Patient Background. Patient background data that could
potentially aﬀect the endpoints were assessed including
age, sex, comorbidities, and type of surgery performed.
Comorbidities assessed included hypertension, diabetes,
chronic heart disease (ischemic heart disease, valvular heart
disease,cardiomyopathy,orcongenitalheartdisease),history
of cerebrovascular diseases (cerebral infarction, cerebral
hemorrhage, or subarachnoid hemorrhage), chronic lung
disease (emphysema, chronic bronchitis, bronchiectasis,
asthma, interstitial lung disease, or pulmonary hyperten-
sion), chronic renal failure, and liver cirrhosis. We also
assessed hospital volume for colorectal cancer surgery
because it could potentially aﬀect postoperative clinical
consequences including mortality and length of stay [25].
Hospital volume was determined as the number of all
the radical surgeries for colorectal cancer during the study
period, using the unique identiﬁer for each hospital.
2.4. Endpoints. “Successful” LTD cases were deﬁned as those
in whom a long tube was ﬁnally removed and who were
discharged home or to a rehabilitation hospital. “Unsuc-
cessful” LTD cases were deﬁned as those who required
secondary laparotomy for removal of adhesion or those who
died during the hospitalization. Two secondary endpoints
were determined as follows: (i) duration of LTD (duration
between long-tube insertion and removal) and (ii) duration
between long-tube insertion and discharge. Another surro-
gate endpoint was total hospital charges. The exchange rate
was assumed to be JP
￿100 = US $1.
2.5. Statistical Analyses. We used propensity score matching
[26] to adjust for diﬀerences in baseline characteristics,
because the patients were not randomly assigned to receive
Dai-kenchu-to. We performed a one-to-one matched analy-
sis onthebasisofestimatedpropensityscoresofeachpatient.
The log odds of the probability that a patient received Dai-
kenchu-to was modeled for potential confounders including
age, sex, comorbidities,type ofsurgery, and hospital volume.
C-statistics were calculated for evaluating the goodness of
ﬁt. The estimated propensity scores were compared between
Dai-kenchu-to users and nonusers, and a “match” occurred
when one patient in the Dai-kenchu-to user group had an
estimated score within 0.6 standard deviation of another
patient in the Dai-kenchu-to nonuser group. If two or more
patients in the Dai-kenchu-to user group met this criterion,
we randomly selected one patient for matching.
We performed univariate comparisons of patient char-
acteristics and outcome variables between the propensity-
score-matched groups of Dai-kenchu-to users and non-
users, using Fisher’s exact tests and t-tests as appropriate.
A logistic regression analysis was performed where the
independent variable was determined as successful LTD
(successful LTD = 1; unsuccessful LTD = 0). We compared
(i) the rates of patients who terminated LTD and (ii) the
rates of patients who were discharged between Dai-kenchu-
tousers and nonusers, using Kaplan-Meiermethods and log-
rank tests. Cox regression analyses were performed to model
the concurrent eﬀect of various factors on (i) termination
of LTD and (ii) discharge. A P value <.05 was considered
statisticallysigniﬁcant. Allstatisticalanalyseswereconducted
using PASW version 18.0 (SPSS Inc.; Chicago, IL, US).
3.Results
We identiﬁed a total of 603 eligible patients who underwent
LTD after colorectal cancer surgery, including Dai-kenchu-
to users (n = 453) and Dai-kenchu-to nonusers (n = 150).
Usingone-to-onepropensityscorematching,weselected144
couples of Dai-kenchu-to users and nonusers. C-statistics
showed that the goodness of ﬁt was 0.592 in this model.
Table 1 shows the patients’ backgrounds in 288 selected
cases of Dai-kenchu-to users and non-users. There were no
signiﬁcant diﬀerences in the patients’ background between
Dai-kenchu-to users and non-users. No Kampo formulation
other than Dai-kenchu-towas administered to any of the288
investigated patients during hospitalization.
LTD was successful in 113 (78.5%) of 144 Dai-kenchu-
to nonusers and 122 (84.7%) of 144 Dai-kenchu-to users. A4 Evidence-Based Complementary and Alternative Medicine
Table 1: Patient background.
Total Dai-kenchu-to nonusers Dai-kenchu-to users P
(N = 288) (N = 144) (N = 144)
Age (average ±SD) 68.2 ±9.66 8 .4 ±10.16 7 .9 ±9.1 .677
Sex (male) (n, %) 213 74.0 110 76.4 103 71.5 .347
Comorbidities (n,% )
Hypertension 53 18.4 28 19.4 25 17.4 .648
Diabetes 48 16.7 24 16.7 24 16.7 1.000
Cardiovascular diseases 16 5.6 8 5.6 8 5.6 1.000
Chronic lung diseases 6 2.1 3 2.1 3 2.1 1.000
Cerebrovascular diseases 2 0.7 1 0.7 1 0.7 1.000
Chronic renal failure 2 0.7 0 0.0 2 1.4 .156
Liver cirrhosis 1 0.3 0 0.0 1 0.7 .316
Type of surgery (n,% )
Colectomy 144 50.0 71 49.3 73 50.7
High anterior resection of rectum 24 8.3 12 8.3 12 8.3 .962
Low anterior resection of rectum 70 24.3 35 24.3 35 24.3
Abdominoperineal resection 50 17.4 26 18.1 24 16.7
Approach
Laparoscopic 21 7.3 11 7.6 10 6.9 .821
Open 267 92.7 133 92.4 134 93.1
Hospital volume for colorectal surgery
(per month; average ± SD) 8.3 ±5.98 .2 ±5.88 .3 ± 6.1 .879
Table 2: Logistic regression analysis for successful long-tube
decompression.
95% conﬁdence
Odds ratio Interval P
Dai-kenchu-to
Nonusers Reference
Users 1.60 0.86–2.95 .137
Age (10-yr age increase) 1.09 0.79–1.51 .592
Sex (Female) 0.52 0.27–1.01 .054
Diabetes 0.73 0.33–1.60 .428
Hypertension 1.07 0.47–2.42 .873
Cardiac diseases 0.45 0.15–1.40 .169
Chronic lung diseases 0.84 0.09–7.74 .879
Hospital volume (per month) 0.99 0.94–1.05 .820
Type of surgery
Colectomy Reference
Rectal of the resection 0.95 0.47–1.94 .893
Abdominoperineal resection 0.62 0.28–1.41 .254
Open or laparoscopic surgery
Open Reference
Laparoscopic 0.85 0.26–2.72 .779
secondary operationwas performed in 48(16.7%) ofthe 288
patients, including 28 (19.4%) in Dai-kenchu-to nonusers
and 20 (13.9%) in Dai-kenchu-to users. In-hospital deaths
were identiﬁedinfour(2.8%)oftheDai-kenchu-tononusers
and two (1.4%) of the Dai-kenchu-to users. Fisher’s exact
tests showed no signiﬁcant diﬀerences in the success rate
of LTD (P = .224), the rate of secondary operation (P =
.206) and in-hospital mortality (P = .684) between the
two groups. Table 2 shows the results of logistic regression
analysis for successfulLTD.The occurrence ofsuccessfulLTD
was not signiﬁcantly diﬀerent between Dai-kenchu-to users
andnonusers(oddsratio,1.60;95%conﬁdenceinterval(CI),
0.86–2.95; P = .137).
The median and interquartile range (IQR) of duration
of LTD was 10 days (6–17 days) in Dai-kenchu-to non-
users and 8 (5–15) days in Dai-kenchu-to users. Figure 1
shows the rate of patients who terminated LTD in relation
to days after long-tube insertion. A log-rank test showed a
signiﬁcant diﬀerence between the groups (P = .012). The
median (IQR) of duration between long-tube insertion and
discharge was longer in Dai-kenchu-to nonusers (25 (19–
36) days) compared with that in Dai-kenchu-to users (23
(18–31) days). Figure 2 shows the rate of patients who were
discharged after long tube insertion. A log-rank test showed
as i g n i ﬁ c a n td i ﬀerence between the groups (P = .018).
Table 3 shows theresults of theCoxregression analyses. After
adjusting for the patient background, the Dai-kenchu-to
user group showed a signiﬁcantly earlier termination of LTD
(hazard ratio, 1.41; 95% CI, 1.08–1.84; P = .011) compared
with the Dai-kenchu-to non-user group; therefore, the
duration of LTD was signiﬁcantly shorter in Dai-kenchu-
to users than that in nonusers. The Dai-kenchu-to user
group showed a signiﬁcantly earlier discharge after long tubeEvidence-Based Complementary and Alternative Medicine 5
Table 3: Cox regression analyses for termination of long-tube decompression and discharge.
Termination of long-tube decompression Discharge
95% conﬁdence 95% conﬁdence
Hazard ratio Interval P Hazard ratio Interval P
Dai-kenchu-to
Nonusers Reference Reference
Users 1.41 1.08–1.84 .011 1.40 1.08–1.83 .012
A g e( 1 0 - y ra g ei n c r e a s e ) 0.99 0.86–1.15 .910 0.90 0.78–1.04 .147
Sex (female) 0.79 0.58–1.09 .150 0.74 0.54–1.01 .058
Diabetes 0.93 0.64–1.35 .701 0.78 0.53–1.13 .186
Hypertension 1.23 0.87–1.74 .248 1.45 1.02–2.04 .036
Cardiac diseases 0.53 0.28–1.03 .060 0.46 0.24–0.87 .016
Cerebrovascular diseases 1.26 0.29–5.42 .757 0.40 0.10–1.68 .211
Chronic lung diseases 0.50 0.20–1.22 .128 0.51 0.21–1.27 .148
Hospital volume per month 1.00 0.98–1.02 .973 1.02 1.00–1.04 .076
Type of surgery
Colectomy Reference Reference
Rectal resection 0.69 0.51–0.94 .018 0.78 0.58–1.05 .097
Abdominoperineal resection 0.72 0.49–1.06 .093 0.71 0.49–1.04 .081
Open or laparoscopic surgery
Open Reference Reference
Laparoscopic 1.27 0.73–2.23 .398 1.37 0.82–2.27 .228
insertion (hazard ratio, 1.40; 95% CI, 1.08–1.83; P = .012)
compared with the Dai-kenchu-to nonuser group; therefore,
the duration between long-tube insertion and discharge was
signiﬁcantly shorter in Dai-kenchu-to users than that in
nonusers.
The mean (±SD) total hospital charges were signiﬁcantly
lower in Dai-kenchu-to users (23,086 ± 9,427 US dollars)
than those in Dai-kenchu-to nonusers (26,950 ± 17,025 US
dollars; P = .018).
4.Discussion
Laparotomy and intestinal manipulation may cause
decreased gastrointestinal motility, delayed gastrointestinal
transit, and intra-abdominal adhesion [1]. Adhesion
may cause mechanical small bowel obstruction, resulting
in prolonged hospitalization and greater health care
utilization [27]. In the Japanese clinical setting, Dai-kenchu-
to is commonly used for prevention and treatment of
postoperative ASBO [6, 7]. Dai-kenchu-to is considered a
safe drug and only a rare incidence of minor side eﬀects has
been reported [6, 18]. The Japanese government has covered
Dai-kenchu-to as a prescription drug under its national
health insurance since 1986, and currently, approximately
500 million Dai-kenchu-to sachets are prescribed annually
in Japan [6].
Few rigorous clinical studies have been performed to
investigate theeﬀectsofKampo regimensagainst any speciﬁc
disease entities [28–30]. Dai-kenchu-to has been shown to
have several pharmacological eﬀects using animal experi-
ments [8–13]. Limited data from several previous clinical
studies have suggested the eﬀectiveness of Dai-kenchu-to in
the preventionofor early recovery from postoperativeASBO
[18–20]. In a previous randomized study of 24 patients with
postoperative ASBO, the frequency of a secondary operation
was signiﬁcantly lower in patients who received Dai-kenchu-
to compared with placebo [18]. In a retrospective study
of 69 patients with postoperative ASBO, the duration of
LTD and average length of stay were signiﬁcantly shorter
in patients who transluminally received Dai-kenchu-to than
those in patients who did not [20]. However, these studies
were based on a small number of patients. The present
larger-scale study demonstrated that administration of Dai-
kenchu-to through a long tube signiﬁcantly reduced the
duration of LTD and hospital stay after long-tube insertion.
Furthermore, the use of Dai-kenchu-to signiﬁcantly reduced
total hospital charges. The success rate of LTD in Dai-
kenchu-to users (84.7%) appeared to be higher than that
in nonusers (78.5%), but this diﬀerence was not signiﬁcant
(P = .224). Although the sample size in our study was
much larger than that in previous studies, our study still
may have been underpowered for identifying a signiﬁcant
reduction in secondary surgery or in-hospital deaths in Dai-
kenchu-to users. Therefore, further study with more samples
is required.
Several limitations to the study should be acknowledged.
Although we used propensity score matching to adjust for
diﬀerences in baseline characteristics, this study was based
on a nonrandomized, retrospective study. We had no data
on obesity, cancer stage, or past history of laparotomies,
which may have aﬀected thediﬃculty of surgical procedures.6 Evidence-Based Complementary and Alternative Medicine
The database also lacked information on some factors that
could potentially aﬀect postoperative consequences, such as
smoking [31].
5.Conclusion
Our propensity-score-matched analysis suggests that Dai-
kenchu-to is eﬀective in terms of reducing the duration of
LTD and saving costs for patients with ASBO after colorectal
cancer surgery. Further study with larger samples or a
randomized controlled trial is necessary for obtaining more
accurate data on this medicine.
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